CHARLESTON, S.C. & OAKDALE, Minn.--(BUSINESS WIRE)--Veravas, Inc., an emerging diagnostic company, today announced the appointment of Carroll E. Streetman Jr., as chief executive officer.
John Forrest, founder and executive chairman, said, “Spearheading the growth of Veravas from conception to launch over the past two years has created a strong momentum for the company, and I am very excited to now have Carroll join our team. His deep experience with clinical and diagnostic operations will be invaluable as we rapidly commercialize our new biotin interference products and advance our innovation pipeline. Prior to taking on this significant role, Carroll has been serving as a valued Veravas advisor and was also an early investor in the company.”
As a seasoned professional with over 45 years of experience, Mr. Streetman brings highly relevant healthcare industry experience to the position. He was president of Full Spectrum Behavior Analysis, LLC, a medical services company, and will remain on their board. Mr. Streetman was president of DiaSorin, the global medical device manufacturing company, where he led their $250 million in vitro diagnostics and medical device manufacturing business. He also served as president and managing partner of CSHC Consultants, LLC where he advised public and private medical diagnostic companies on business development strategies, technology acquisition, product development, and manufacturing. Prior to that, he was chief operating officer of HCA Healthcare Corporation where he managed and directed operations, sales, and marketing for the managed care services provider. While at DiaSorin, Mr. Streetman worked with Josh Soldo, chief scientific officer at Veravas.
“Through my time leading diagnostic and clinical companies, I have become increasingly passionate about the way accurate diagnostics inform better care and improve health outcomes. I’m thrilled to be joining a team that is transforming the practice of laboratory medicine in a way that will impact and benefit the entire health ecosystem,” said Mr. Streetman. “I look forward to working with this talented team to further commercialize Veravas’ sample preparation technology, develop novel diagnostic assays, and nurture partnerships to bring the company’s solutions into clinical practice.”
About Veravas
Veravas is transforming laboratory medicine with technology that delivers superior test results, providing confidence to clinicians and patients that diagnoses are accurate. The company is rapidly driving the commercialization of proprietary sample preparation products and new diagnostic tests. Veravas’ nano magnetic particles can identify, remove, and measure select substances from patient samples to reduce the effects of complex interferences and detect low-abundance biomarkers. Led by a passionate and dedicated team, Veravas is devoted to improving patient lives by minimizing the harmful effects of unnecessary treatments and deaths associated with poor quality diagnostic results. Because every patient deserves the correct result, every time. To learn more about our technologies and clinical applications, visit veravas.com.